463 related articles for article (PubMed ID: 27862103)
1. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
Boucher BA; Hudson JQ; Hill DM; Swanson JM; Wood GC; Laizure SC; Arnold-Ross A; Hu ZY; Hickerson WL
Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103
[TBL] [Abstract][Full Text] [Related]
2. Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD).
Vos MC; Vincent HH; Yzerman EP
Intensive Care Med; 1992; 18(5):282-5. PubMed ID: 1527259
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.
Tegeder I; Bremer F; Oelkers R; Schobel H; Schüttler J; Brune K; Geisslinger G
Antimicrob Agents Chemother; 1997 Dec; 41(12):2640-5. PubMed ID: 9420033
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic Modeling and Simulations of Imipenem in Burn Patients With and Without Continuous Venovenous Hemofiltration in the Military Health System.
Por ED; Akers KS; Chung KK; Livezey JR; Selig DJ
J Clin Pharmacol; 2021 Sep; 61(9):1182-1194. PubMed ID: 33811332
[TBL] [Abstract][Full Text] [Related]
5. Using imipenem and cilastatin during continuous renal replacement therapy.
Cotton A; Franklin BD; Brett S; Holmes A
Pharm World Sci; 2005 Oct; 27(5):371-5. PubMed ID: 16341743
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients.
Fish DN; Teitelbaum I; Abraham E
Antimicrob Agents Chemother; 2005 Jun; 49(6):2421-8. PubMed ID: 15917542
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration.
Alarabi AA; Cars O; Danielson BG; Salmonson T; Wikström B
J Antimicrob Chemother; 1990 Jul; 26(1):91-8. PubMed ID: 2211452
[TBL] [Abstract][Full Text] [Related]
8. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration.
Mueller BA; Scarim SK; Macias WL
Am J Kidney Dis; 1993 Feb; 21(2):172-9. PubMed ID: 8430678
[TBL] [Abstract][Full Text] [Related]
9. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients.
Keller E; Fecht H; Böhler J; Schollmeyer P
Nephrol Dial Transplant; 1989; 4(7):640-5. PubMed ID: 2510062
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of imipenem/cilastatin during continuous arteriovenous hemofiltration.
Przechera M; Bengel D; Risler T
Contrib Nephrol; 1991; 93():131-4. PubMed ID: 1802563
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.
Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):85-8. PubMed ID: 1864280
[TBL] [Abstract][Full Text] [Related]
12. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
Sakka SG; Glauner AK; Bulitta JB; Kinzig-Schippers M; Pfister W; Drusano GL; Sörgel F
Antimicrob Agents Chemother; 2007 Sep; 51(9):3304-10. PubMed ID: 17620371
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid.
Janssen PK; Foudraine NA; Burgers DM; Neef K; le Noble JL
Ther Drug Monit; 2016 Dec; 38(6):699-705. PubMed ID: 27494946
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis.
Bergan T; Michalsen H; Malmborg AS; Pedersen SS; Pressler T; Storrøsten OT; Strandvik B
Chemotherapy; 1993; 39(6):369-73. PubMed ID: 8222862
[TBL] [Abstract][Full Text] [Related]
17. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients.
Guenter SG; Iven H; Boos C; Bruch HP; Muhl E
Pharmacotherapy; 2002 Feb; 22(2):175-83. PubMed ID: 11837556
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill.
Hashimoto S; Honda M; Yamaguchi M; Sekimoto M; Tanaka Y
ASAIO J; 1997; 43(1):84-8. PubMed ID: 9116359
[TBL] [Abstract][Full Text] [Related]
20. Imipenem pharmacokinetics in patients with burns.
Boucher BA; Hickerson WL; Kuhl DA; Bombassaro AM; Jaresko GS
Clin Pharmacol Ther; 1990 Aug; 48(2):130-7. PubMed ID: 2379384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
